Index
Peptide monographs
37 entries. Filter by class or search by name, alias, or chemical classification.
| Name | Class | MW | Half-life | Category |
|---|---|---|---|---|
| 3X Blend (Tesa / Ipa / MGF) Tesamorelin + Ipamorelin + MGF 5/2.5/0.5 | GHRH + GH-secretagogue + mechano-growth factor blend | Tesamorelin 5196; Ipamorelin 712; MGF ≈ 2868 g/mol | Tesamorelin ≈ 26 min; Ipamorelin ≈ 2 h; MGF ≈ 5–7 min | Multi-Peptide Blends |
| AOD-9604 | hGH(177-191) C-terminal fragment | 1817.1 g/mol | Short (minutes, plasma) | Metabolic & Incretin |
| BPC-157 Body Protection Compound 157 · PL 14736 | Pentadecapeptide fragment of gastric BPC | 1419.5 g/mol | ≈ 30 min (plasma, preclinical) | Healing & Tissue Repair |
| Cagrilintide AM833 | Long-acting amylin analogue | ≈ 3950 g/mol | ≈ 7 days | Metabolic & Incretin |
| CJC-1295 DAC:GRF · Modified GRF (1-29) | GHRH analogue (with or without Drug Affinity Complex) | 3367.9 g/mol (with DAC) | ≈ 8 days (with DAC); ≈ 30 min (without) | Growth Hormone Secretagogues |
| CJC-1295 / Ipa 2X Blend (10mg / 10mg) CJC-1295 No-DAC + Ipamorelin 10/10 | GHRH analogue (no-DAC) + GH-secretagogue blend (high-dose) | CJC-1295 No-DAC 3367 g/mol; Ipamorelin 711.9 g/mol | CJC-1295 No-DAC ≈ 30 min; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| CJC-1295 / Ipa 2X Blend (5mg / 5mg) CJC-1295 No-DAC + Ipamorelin 5/5 · Mod-GRF(1-29) + Ipamorelin | GHRH analogue (no-DAC) + selective GH-secretagogue blend | CJC-1295 No-DAC 3367 g/mol; Ipamorelin 711.9 g/mol | CJC-1295 No-DAC ≈ 30 min; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| Dihexa N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408 | Angiotensin IV analogue (oligopeptide) | 473.6 g/mol | Oral bioavailability reported; pharmacokinetics in humans not published | Cognitive & Neurotrophic |
| DSIP Delta Sleep-Inducing Peptide | Nonapeptide neuromodulator | 848.8 g/mol | ≈ 7–15 min (plasma) | Cognitive & Neurotrophic |
| Epitalon Epithalon · Epithalamin tetrapeptide | Synthetic tetrapeptide | 390.35 g/mol | Short (minutes) | Longevity & Mitochondrial |
| GHK-Cu Copper Tripeptide-1 | Copper-binding tripeptide | 402.92 g/mol (complex) | Short (topical/local activity) | Healing & Tissue Repair |
| GLOW Blend (GHK-Cu / BPC-157 / TB-500) GLOW 70 · GHK-Cu + BPC-157 + TB-500 50/10/10 | Skin & soft-tissue regenerative blend | GHK 340 g/mol (with Cu²⁺ ≈ 402); BPC-157 ≈ 1419; TB-500 ≈ 4960 g/mol | GHK-Cu minutes (rapid tissue uptake); BPC-157 ≈ 4 h; TB-500 ≈ 2–3 h | Multi-Peptide Blends |
| Glucagon | 29-amino-acid pancreatic peptide hormone | 3482.8 g/mol | ≈ 3–6 min (IV) | Metabolic & Incretin |
| Hexarelin | Synthetic GH-releasing hexapeptide (GHRP) | 887.05 g/mol | ≈ 70 min (IV) | Growth Hormone Secretagogues |
| IGF-1 LR3 Long-R3-IGF-1 | Modified recombinant insulin-like growth factor 1 | 9111 g/mol | ≈ 20–30 h (extended vs. native IGF-1) | Growth Hormone Secretagogues |
| Ipamorelin | Selective ghrelin/GHS-R1a agonist | 711.86 g/mol | ≈ 2 h | Growth Hormone Secretagogues |
| KLOW Blend (GHK-Cu / BPC-157 / TB-500 / KPV) KLOW 80 · GLOW + KPV | Regenerative + immune-modulating blend | Composite; KPV 342.4 g/mol | GHK-Cu minutes; BPC-157 ≈ 4 h; TB-500 ≈ 2–3 h; KPV short systemic | Multi-Peptide Blends |
| KPV α-MSH(11-13) | C-terminal tripeptide fragment of α-MSH | 342.4 g/mol | Short (minutes) | Immune & Thymic |
| Melanotan-1 MT-1 · Afamelanotide | α-MSH analogue (melanocortin agonist) | 1646.8 g/mol | ≈ 30 min (free); sustained-release implant approved | Cognitive & Neurotrophic |
| Melanotan-2 MT-2 | Cyclic α-MSH analogue (non-selective melanocortin agonist) | 1024.2 g/mol | ≈ 33 min | Cognitive & Neurotrophic |
| MOTS-c | Mitochondrial-derived peptide (MDP) | 2174.6 g/mol | Short (preclinical) | Longevity & Mitochondrial |
| NAD+ Nicotinamide Adenine Dinucleotide | Pyridine dinucleotide coenzyme (not a peptide) | 663.4 g/mol | Tissue-specific; intracellular pool turns over within hours | Longevity & Mitochondrial |
| Oxytocin | Nonapeptide neuropeptide / hormone | 1007.2 g/mol | ≈ 1–6 min (IV); ≈ 20 min (intranasal CNS effects) | Cognitive & Neurotrophic |
| PT-141 Bremelanotide | Melanocortin receptor agonist | 1025.2 g/mol | ≈ 2.7 h | Cognitive & Neurotrophic |
| Retatrutide LY3437943 · GLP-1/GIP/Glucagon triple agonist | Triple GLP-1 / GIP / Glucagon receptor agonist | ≈ 4900 g/mol | ≈ 6 days | Metabolic & Incretin |
| Selank | Synthetic tuftsin analogue | 751.9 g/mol | Short (minutes, intranasal) | Cognitive & Neurotrophic |
| Semaglutide | GLP-1 receptor agonist (incretin mimetic) | 4113.6 g/mol | ≈ 165 h (≈ 1 week) | Metabolic & Incretin |
| Semax | Synthetic ACTH(4-10) analogue | 813.9 g/mol | Short (minutes, intranasal); CNS effects persist hours | Cognitive & Neurotrophic |
| Sermorelin GHRH(1-29) · GRF 1-29 | GHRH(1-29) analogue | 3358 g/mol | ≈ 10–20 min (SC) | Growth Hormone Secretagogues |
| SS-31 Elamipretide · MTP-131 · Bendavia | Mitochondria-targeted tetrapeptide | 639.8 g/mol | ≈ 2–4 h (SC) | Longevity & Mitochondrial |
| TB-500 Thymosin Beta-4 fragment | Synthetic fragment of Thymosin β4 | ≈ 889 g/mol (fragment) | 2–3 h (preclinical) | Healing & Tissue Repair |
| Tesa/Ipa 2X Blend (12mg / 3mg) Tesamorelin + Ipamorelin 12/3 | GHRH-dominant + GH-secretagogue blend | Tesamorelin 5196 g/mol; Ipamorelin 711.9 g/mol | Tesamorelin ≈ 26 min; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| Tesa/Ipa 2X Blend (5mg / 5mg) Tesamorelin + Ipamorelin 5/5 | GHRH analogue + selective GH-secretagogue blend | Tesamorelin 5196 g/mol; Ipamorelin 711.9 g/mol | Tesamorelin ≈ 26 min systemic; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| Tesamorelin | Stabilized GHRH(1-44) analogue | 5135.9 g/mol | ≈ 26 min (SC) | Growth Hormone Secretagogues |
| Thymosin α1 Tα1 · Thymalfasin | Thymic peptide | 3108.3 g/mol | ≈ 2 h (SC) | Immune & Thymic |
| Tirzepatide | Dual GIP / GLP-1 receptor agonist | 4813.5 g/mol | ≈ 120 h (≈ 5 days) | Metabolic & Incretin |
| Wolverine Blend (BPC-157 / TB-500) BPC-157 + TB-500 · Wolverine 20mg | Tissue-repair co-lyophilized blend | BPC-157 ≈ 1419 g/mol; TB-500 (fragment) ≈ 4960 g/mol | BPC-157 ≈ 4 h; TB-500 ≈ 2–3 h (parent fragment) | Multi-Peptide Blends |